UroToday

LenCabo Phase II Trial Investigates Lenvatinib-Everolimus vs Cabozantinib in Relapsed Kidney Cancer - Andrew Hahn

Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...
UroToday

MRI-targeted Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

Comparing Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia - Dean Elterman

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday

Artera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test

Data from Artera’s DIRECT-AI registry will assess the test’s impact on cancer care and guide future improvements Reno, Nevada (UroToday.com) -- Artera, the developer of multimodal artificial ...
UroToday

FAP and Nectin-4 Targeted Imaging and Therapy in Urothelial Cancer "Presentation" - Vadim Koshkin

At the 2025 UCSF-UCLA PSMA Conference, Vadim Koshkin discusses radioligand therapies for bladder cancer. He highlights that gallium-FAP-2286 imaging shows bladder cancer has the highest FAP uptake ...
UroToday

The Details Are in the Core: Advancing Prostate Tissue Collection - James Wysock

James Wysock joins Zachary Klaassen to discuss improving prostate cancer diagnostics through better biopsy needle technology. Dr. Wysock highlights early experience with the SUREcore® Biopsy Needle ...
UroToday

Clinical Experience with Actinium-PSMA Across Multiple Treatment Centers "Presentation" - Alfred Morgenstern

At the 2025 UCSF-UCLA PSMA Conference, Alfred Morgenstern discusses his work with actinium-PSMA therapy for prostate cancer. He reviews clinical programs including Mike Sathekge's work with ...
UroToday

Lutetium PSMA Beyond Six Cycles Extended Treatment and Re-Challenge Approaches "Presentation" - Matthias Eiber

At the 2025 UCSF-UCLA PSMA Conference, Matthias Eiber discusses lutetium PSMA therapy beyond six standard cycles. He distinguishes between extended treatment (continuous administration) and ...
UroToday

Can We Kill the Bone Scan? "Presentation" - Daniel Spratt

At the 2025 UCSF-UCLA PSMA Conference, Daniel Spratt presents on bone scan obsolescence in prostate cancer imaging. He demonstrates they fail to detect cancer with sufficient sensitivity compared to ...
UroToday

Transvaginal Detrusor Nerve Radiofrequency Ablation for Overactive Bladder.

Autonomic nerves and ganglia that affect bladder sensation and detrusor contractility are present below the proximal urethra and trigone. Radiofrequency energy has been shown to potentially ...
UroToday

Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer in the US - Umang Swami

Read the Full Video Transcript Neeraj Agarwal: Welcome to another UroToday episode. Here we have Dr. Umang Swami, who is a faculty in oncology division at the Huntsman Cancer Institute at the ...
UroToday

PARASEC Study Reveals Real-World Treatment Patterns After Darolutamide in ARAMIS Trial - Javier Puente

Zachary Klaassen hosts Javier Puente to discuss the PARASEC trial. Dr. Puente describes this retrospective observational study examining treatment patterns of patients who received darolutamide in the ...